BG
Bellevue Group Portfolio holdings
AUM
$5.28B
1-Year Est. Return
50.12%
This Fund
S&P 500
1 Year Est. Return
+50.12%
AUM
$4.81B
AUM Growth
+$276M
(+6.1%)
Holding
159
Top Buys
| 1 | +$87M | |
| 2 | +$38.9M | |
| 3 | +$26.8M | |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$19.6M |
| 5 |
Immunocore
IMCR
|
+$12.1M |
Top Sells
| 1 | +$93.6M | |
| 2 | +$78.5M | |
| 3 | +$36.5M | |
| 4 |
Moderna
MRNA
|
+$34.3M |
| 5 |
Stryker
SYK
|
+$32.5M |
Sector Composition
| 1 | Healthcare | 99.85% |
| 2 | Technology | 0.03% |
| 3 | Consumer Discretionary | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Arcutis Biotherapeutics
ARQT
$2.99B
| – | – |
-24,008
|
|
||
152
Black Diamond Therapeutics
BDTX
$132M
| – | – |
-2,733,547
|
|
||
|
BPMC
153
DELISTED
Blueprint Medicines
BPMC
| – | – |
-284,900
|
|
||
154
BellRing Brands
BRBR
$2.05B
| – | – |
-3,500
|
|
||
155
Novo Nordisk
NVO
$162B
| – | – |
-6,500
|
|
||
156
Oculis Holding
OCS
$1.58B
| – | – |
-9,700
|
|
||
157
Travere Therapeutics
TVTX
$2.56B
| – | – |
-18,303
|
|
||
|
VRNA
158
DELISTED
Verona Pharma
VRNA
| – | – |
-15,927
|
|
||
|
MTSR
159
DELISTED
Metsera Inc
MTSR
| – | – |
-7,800
|
|